Scholars Central

Conference abstractPublished 27 Jul 2018

Challenges and solutions for maintaining quality and potency of the product in vaccine development

Authors: Laura Hong

Merck & Co, Inc, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The quality of vaccines is increasingly guaranteed by the use of robust and reproducible production processes. FDA and other regulatory agencies generated recommendations and guidelines to ensure high quality levels. The present talk will be focus on the discussions of the following areas: âÂ?¢ Why need to assess the quality and the potency of vaccine product from early phase through the late phase vaccine development, even after licensure of the product âÂ?¢ Strategy thinking and planning in the assessment of the potency and safety of Human Vaccine: in vivo animal assay vs. in vitro assays. âÂ?¢ Cases studies to demonstrate the challenges and solutions to timely evaluate the quality and potency of vaccine products. âÂ?¢ Regulatory considerations of the potency evaluation of vaccine products

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalVirology & Mycology
  • SubjectInfectious Diseases
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Laura Hong”